Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 4/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10094455 | 0.87 | NPC1 (0.51) | HTR7KLKB1NPC1RAB9AMEN1 | |
| SCHEMBL10094380 | 0.85 | BRD4 (0.52) | BRD4CREBBPL3MBTL1SMYD3NPC1 | |
| SCHEMBL10094517 | 0.79 | PARP1 (0.53) | BRD4PARP1NPC1RAB9AFAAH | |
| SCHEMBL10094443 | 0.77 | KCNA5 (0.51) | BRD4CREBBP | |
| SCHEMBL1116603 | 0.77 | GRM5 (0.77) | GRM5HTR2BL3MBTL1SMYD3NPC1 | |
| SCHEMBL27769316 | 0.76 | KAT6A (0.55) | GRM5HTR7BRD4CREBBPL3MBTL1 | |
| SCHEMBL105413 | 0.76 | TAS1R3 (0.53) | NPC1RAB9AKMT2A | |
| SCHEMBL20371607 | 0.75 | MAPK14 (0.52) | BRD4CREBBPL3MBTL1SMYD3NPC1 | |
| SCHEMBL15730263 | 0.75 | MAPK14 (0.56) | GRM5BRD4CREBBPSMYD3NPC1 | |
| SCHEMBL10094449 | 0.75 | HSP90AA1 (0.51) | BRD4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148535-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | PIM1 2003/4885PIM2 1446/4885GRM5 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.